Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of pazopanib plus ifosfamide in advanced solid malignancies
NL-OMON28441Phase 1Recruiting
- Sponsor
- Erasmus MC
- Start
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pazopanib and ifosfamide in Nonhematologic neoplasms and Bone and soft tissue sarcoma (2 arms), sponsored by Erasmus MC. Primary endpoint: Maximum tolerated dose. Started Jun 2009; status: recruiting.
02
Drugs
pazopanibifosfamide
03
Conditions
Nonhematologic neoplasmsBone and soft tissue sarcoma
Beyond the preview
Go deeper on NL-OMON28441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28441.